Dudnyk buys device-marketing expert Stratagem

Share this article:
Dudnyk bought San Francisco-based Stratagem Healthcare Communications in a move to bolster its West Coast presence and add medical-device marketing expertise, the ad agency said. Terms were not disclosed.

The formerly independent Stratagem will operate within the structure of Dudnyk's brand, and several key Stratagem personnel will join the new owners.

The northern California acquisition follows Dudnyk's move in February to open a southern California outpost, aimed at servicing clients such as Medtronic Diabetes, added to the roster this year.

“Our focus is communicating with specialty physicians and their patients in the biotech, biopharma, and medical device sectors,” said Frank Powers, Dudnyk president (pictured below), in a statement about the acquisition. “The Stratagem team brings us additional senior talent and experience with those audiences and sectors; additional imaging, dermatology, and medical device marketing expertise; plus a strong direct-to-patient (DTP) portfolio.”

Strategem accounts include ZONARE Medical Systems, John Muir Health, Valeant Pharmaceuticals and Roche Molecular Systems.

Dudnyk “will bring creative, digital, and scientific energy to our clients,” said Susan Hempstead, a former Stratagem exec who is now joining Dudnky as SVP, account management and strategy. Among her colleagues staying on at the northern California shop are Patricia Malone, SVP, creative director, copy, and Paul Harris, SVP, creative director, art.

An independently owned healthcare agency, Dudnyk is based in Horsham, PA, and also has a full-service office in Carlsbad, California, located between San Diego and Los Angeles. Among additional clients added this year were Carticept, for an orthopedic device launch.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union